(Q24202812)

1

0 references

Bongani Mayosi

4

object named as

Bongani M Mayosi

0 references

Lionel Opie

6

object named as

Lionel H Opie

0 references

author name string

Hazel A Bradley

2

0 references

Anthony Mbewu

Cochrane Database of Systematic Reviews

5

0 references

publication date

14 November 2012

0 references

published in

0 references

cites work

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

The Medical Research Council Hypertension Trial: the smoking patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

The combination therapy of hypertension to prevent cardiovascular events (COPE) trial: rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Blood pressure response under chronic antihypertensive drug therapy: the role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Comparative analysis of beta-blockers with other antihypertensive agents on cardiovascular outcomes in hypertensive patients with diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Science, medicine, and the future. Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Atenolol in hypertension: is it a wise choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Calcium channel blockers versus other classes of drugs for hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Blood pressure, stroke, and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Rethinking the "diseases of affluence" paradigm: global patterns of nutritional risks in relation to economic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

β-blockers in hypertension—the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Evidence is needed that beta blockade alone reduces mortality in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Old antihypertensives and new diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

The vasodilatory beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

British Hypertension Society guidelines for hypertension management 1999: summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Adverse prognostic significance of new diabetes in treated hypertensive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Evidence-based medicine in hypertension: what type of evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Beta-blockers for hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

First-line diuretics versus other classes of antihypertensive drugs for hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

The international prospective primary prevention study in hypertension (IPPPSH): objectives and methods. The IPPPSH Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Beta-blockers versus saluretics in hypertension. Comparison of total mortality, myocardial infarction, and sudden death: study design and early results on blood pressure reduction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

beta-blockers or diuretics in hypertension? A six year follow-up of blood pressure and metabolic side effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Blood-pressure control in the hypertensive population

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

STOP-hypertension: Swedish trial in old patients with hypertension.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

The Captopril Prevention Project: a prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. The CAPPP Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Thiazide diuretics and β-blockers in the treatment of hypertension in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Randomised trial of treatment of hypertension in elderly patients in primary care

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. Medical Research Council Working Party on Mild Hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Decreased coronary heart disease in hypertensive smokers. Mortality results from the MAPHY study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021

The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB4

7 January 2021